Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities

What is it about?

Two classes of diabetes medications have been demonstrated to reduce the risks of cardiovascular disease, heart failure, and kidney disease in patients living with type 2 diabetes. We examined whether these medications, GLP-1 receptor agonists and SGLT2 inhibitors, are more likely to be started by patients with these comorbidities as compared to DPP-4 inhibitors, which do not have similar benefits.

Featured Image